Xeris Biopharma Holdings (XERS) Stock Price, Quote, News & History

Comments

Xeris Biopharma Holdings Inc (XERS) Stock Price, Quote, News & History

XERSNASDAQ

Trade with Public

$6.04

N/A

At close: Apr 2, 5:00 PM EST

$6.04

N/A

After Hours: 4:00 PM EST

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$5.90

Close

$6.04

Volume / Avg.

1.34M / 2.09M

Day Range

$5.88 - $6.14

52 Wk Range

3.81 - 10.08

Market Cap

$1.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

10.16%

Days to Cover

6.77

Recent Xeris Biopharma Holdings Inc News

Why Are Shares Of Xeris Biopharma Falling Friday?

Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.

Alex Perry

Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Avi Kapoor

More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

28.63M

Investing Cash Flow (TTM)

-696.00K

Financing Cash Flow (TTM)

11.39M

Free Cash Flow (TTM)

27.93M

Capital Expenditure (TTM)

-696.00K

Net Change in Cash (TTM)

39.32M

Analyst Trends and Forecast

1

Oct 25

2

1

Nov 25

1

Dec 25

1

Jan

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.19B

PE Ratio (TTM)

-

PE Ratio (FWD)

80.65

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.58

PB Ratio (TTM)

76.08

Earnings Yield % (TTM)

0.00%

Earnings Yield % (FWD)

1.24%

EV / EBITDA (TTM)

28.08

Price / EBITDA (TTM)

24.65

Price / Free Cash Flow (TTM)

37.36

Book Value / Share

$0.08

Company Debt

Total Debt

$220.34M

LT Debt

$220.34M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

$0

Total Cash

$111.04M

Debt to Equity

18.85

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

$0

Key Statistics

Open

$5.90

Close

$6.04

Volume / Avg.

1.34M / 2.09M

Day Range

$5.88 - $6.14

52 Wk Range

3.81 - 10.08

Market Cap

$1.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

10.16%

Days to Cover

6.77

About

Sector

Health Care

Industry

Pharmaceuticals

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Xeris Biopharma Holdings (XERS) stock?

A

You can purchase shares of Xeris Biopharma Holdings (NASDAQ:XERS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Xeris Biopharma Holdings (XERS) competitors?

A

Other companies in Xeris Biopharma Holdings’s space includes: Theravance Biopharma Inc (NASDAQ:TBPH), GH Research PLC (NASDAQ:GHRS), AtaiBeckley Inc (NASDAQ:ATAI), Bioage Labs Inc (NASDAQ:BIOA) and WAVE Life Sciences Ltd (NASDAQ:WVE).

Q

What is the forecast, or price target, for Xeris Biopharma Holdings (XERS) stock?

A

Xeris Biopharma Holdings has a consensus price target of $9.28.

Q

What is the current price for Xeris Biopharma Holdings (XERS)?

A

The stock price for Xeris Biopharma Holdings (NASDAQ: XERS) is $6.04 last updated April 2, 2026 at 4:00 PM EDT.

Q

Does Xeris Biopharma Holdings (XERS) pay a dividend?

A

There are no upcoming dividends for Xeris Biopharma Holdings.

Q

When is Xeris Biopharma Holdings (NASDAQ:XERS) reporting earnings?

A

Xeris Biopharma Holdings does not have any upcoming earnings scheduled.

Q

Is Xeris Biopharma Holdings (XERS) going to split?

A

There is no upcoming split for Xeris Biopharma Holdings.

Q

What sector and industry does Xeris Biopharma Holdings (XERS) operate in?

A

Xeris Biopharma Holdings is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Theravance Biopharma Inc

WAVE Life Sciences Ltd

NASDAQ:WVE

$7.16

-1.65%

Rapport Therapeutics Inc

NASDAQ:RAPP

$33.58

%

Phathom Pharmaceuticals Inc

Key Statistics

Open

$5.90

Close

$6.04

Volume / Avg.

1.34M / 2.09M

Day Range

$5.88 - $6.14

52 Wk Range

3.81 - 10.08

Market Cap

$1.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

10.16%

Days to Cover

6.77

Recent Xeris Biopharma Holdings Inc News

Why Are Shares Of Xeris Biopharma Falling Friday?

Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.

Alex Perry

Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Avi Kapoor

More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

28.63M

Investing Cash Flow (TTM)

-696.00K

Financing Cash Flow (TTM)

11.39M

Free Cash Flow (TTM)

27.93M

Capital Expenditure (TTM)

-696.00K

Net Change in Cash (TTM)

39.32M

Analyst Trends and Forecast

1

Oct 25

2

1

Nov 25

1

Dec 25

1

Jan

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.19B

PE Ratio (TTM)

-

PE Ratio (FWD)

80.65

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.58

PB Ratio (TTM)

76.08

Earnings Yield % (TTM)

0.00%

Earnings Yield % (FWD)

1.24%

EV / EBITDA (TTM)

28.08

Price / EBITDA (TTM)

24.65

Price / Free Cash Flow (TTM)

37.36

Book Value / Share

$0.08

Company Debt

Total Debt

$220.34M

LT Debt

$220.34M

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

$0

Total Cash

$111.04M

Debt to Equity

18.85

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

$0

Key Statistics

Open

$5.90

Close

$6.04

Volume / Avg.

1.34M / 2.09M

Day Range

$5.88 - $6.14

52 Wk Range

3.81 - 10.08

Market Cap

$1.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

10.16%

Days to Cover

6.77

About

Sector

Health Care

Industry

Pharmaceuticals

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry